Senexis

Senexis Limited, a private drug development company announced today that it has filed two further patents to protect its latest generation of bioavailable and CNS-penetrant small-molecule compounds, as a potential disease-modifying treatment for Alzheimer’s disease. The compounds are neuroinflammation inhibitors for the potential treatment of the later stages of Alzheimer’s disease.

David Scopes, Senexis’ Chief Scientific Officer, commented: “we believe that that these novel compounds inhibit the inappropriate inflammation of the brain that can be triggered by amyloid. We now look forward to being able to accelerate the development of these small molecule compounds towards the clinic.”

About Senexis

Senexis is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer’s and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Further information on Senexis can be found at www.senexis.com.